Abattis Bioceuticals Corp. (ATTBF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAbattis Bioceuticals Corp. (ATTBF) trades at $0.00003. Abattis Bioceuticals Corp. is a Canadian life sciences and biotechnology company focused on developing and licensing natural health products, medicines, extractions, and ingredients for diverse markets. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for ATTBF: ATTBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Abattis Bioceuticals Corp. (ATTBF) Healthcare & Pipeline Overview
Abattis Bioceuticals Corp. is a Canadian life sciences and biotechnology company focused on developing and licensing natural health products, medicines, extractions, and ingredients for diverse markets including nutraceutical, bioceutical, and cosmetic. It also provides cannabinoid-enhanced nutraceuticals and Health Canada licensed services for the cannabis industry.
What Is the Investment Thesis for ATTBF?
Abattis Bioceuticals Corp. operates within the Canadian life sciences and biotechnology sectors, focusing on the development and licensing of natural health products, specialized medicines, and ingredients for diverse markets including nutraceuticals and cosmetics. A key value driver lies in its proprietary cannabinoid-enhanced nutraceutical, Comfort, targeting the pain and inflammation market, alongside its provision of Health Canada licensed services to the cannabis industry. The company's gross margin of 67.6% indicates strong product-level profitability, despite an overall profit margin of -852.4%, suggesting operational inefficiencies or significant investment phases. Potential growth catalysts include increased market penetration for Comfort, expansion of its licensing agreements for natural health products, and a growing demand for Health Canada compliant services within the evolving cannabis sector. However, the company's current market capitalization of $0.00B and negative profit margin present significant risk factors, indicating a need for substantial operational improvements and capital infusion to achieve sustained profitability and scale. The high negative beta of -46.51 suggests an unusual inverse relationship with market movements, which warrants further investigation.
Based on FMP financials and quantitative analysis
ATTBF Key Highlights
Market Capitalization: $0.00B, indicating a micro-cap or non-reporting entity status.
- Profit Margin: -852.4%, reflecting substantial net losses relative to revenue.
- Gross Margin: 67.6%, demonstrating strong profitability at the product or service cost level before operating expenses.
- Beta: -46.51, an exceptionally high negative value suggesting an inverse and highly volatile relationship with the broader market.
- Dividend Policy: The company does not currently pay a dividend.
Who Are ATTBF's Competitors?
ATTBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.50 | -4.76% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.47 | -0.29% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.50 | +0.86% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.82 | +2.01% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $5.83 | -7.61% | $25.5M | — |
| YI 111, Inc. | $3.17 | -1.55% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.33 | -1.84% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ATTBF's Key Strengths?
Diversified product and service portfolio across natural health, nutraceuticals, and cannabis industry services.
- Possession of Health Canada licensed services, providing a competitive advantage in the regulated cannabis sector.
- Proprietary cannabinoid-enhanced nutraceutical product ("Comfort") addressing specific health needs.
- Strong gross margin of 67.6% indicates efficient cost management at the product level.
What Are ATTBF's Weaknesses?
Extremely negative profit margin of -852.4%, indicating significant operational losses.
- Market capitalization of $0.00B suggests a very small or non-reporting entity, potentially limiting access to capital.
- Trades on the OTC market, which often implies lower liquidity and less stringent reporting requirements.
- High negative Beta of -46.51, an unusual financial metric that may signal extreme volatility or data anomalies.
What Are the Key Risks for ATTBF?
Financial-distress signal — its Altman Z-Score of -7.97 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-27.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- **Ongoing**: Significant financial losses, as evidenced by a -852.4% profit margin, posing a risk to long-term sustainability and requiring substantial capital.
- **Ongoing**: Challenges associated with operating on the OTC Other tier, including limited liquidity, potential for extreme volatility, and difficulty in attracting institutional investment.
- **Potential**: Regulatory changes or increased scrutiny in the natural health, nutraceutical, or cannabis sectors could impact product approvals or service demand.
- **Potential**: Intense competition from larger, better-capitalized companies in the life sciences and biotechnology sectors.
- **Ongoing**: Uncertainty regarding the availability and transparency of financial disclosures, given the "Unknown" disclosure status on the OTC market.
What Are ATTBF's Competitive Advantages?
- **Specialized Licensing Expertise**: Holds Health Canada licenses for services within the cannabis industry, a significant regulatory barrier to entry.
- **Proprietary Product Development**: Development of specific cannabinoid-enhanced nutraceuticals like "Comfort" offers unique product differentiation.
- **Diverse Market Focus**: Addresses multiple high-growth markets (nutraceutical, bioceutical, cosmetic, cannabis services) diversifying revenue potential.
- **Intellectual Property in Natural Health**: Focus on developing and licensing natural health products and ingredients creates a portfolio of proprietary assets.
What Does ATTBF Do?
Abattis Bioceuticals Corp., headquartered in Vancouver, Canada, operates as a life sciences and biotechnology company with a history dating back to its incorporation in 1997. Initially known as Abattis Biologix Corporation, the company underwent a name change to Abattis Bioceuticals Corporation in September 2012, reflecting its evolving strategic focus. The company's core business revolves around the development and licensing of a diverse portfolio of natural health products, specialized medicines, botanical extractions, and various ingredients. These offerings are specifically tailored for a broad spectrum of markets, including the biological, nutraceutical, bioceutical, and cosmetic sectors. This multi-market approach allows Abattis to address various consumer health and wellness needs, from dietary supplements to advanced cosmetic formulations. Beyond its product development and licensing activities, Abattis Bioceuticals Corp. also directly provides a cannabinoid-enhanced nutraceutical product named "Comfort," which is marketed for its potential benefits in addressing pain and inflammation. This product positions the company within the rapidly expanding market for cannabis-derived health solutions, albeit within the nutraceutical framework. Furthermore, the company extends its operational scope by offering Health Canada licensed services specifically designed for the cannabis industry. These services are crucial for businesses operating in Canada's regulated cannabis sector, providing essential support and compliance solutions. This dual focus on proprietary product development and specialized industry services underscores Abattis Bioceuticals Corp.'s position as a multifaceted player in the Canadian life sciences and biotechnology landscape, leveraging its expertise across natural health, cannabis, and broader bioceutical applications.
What Products and Services Does ATTBF Offer?
- Develops natural health products, medicines, extractions, and ingredients.
- Licenses these products and ingredients to other companies.
- Focuses on the biological, nutraceutical, bioceutical, and cosmetic markets.
- Offers "Comfort," a cannabinoid-enhanced nutraceutical for pain and inflammation.
- Provides Health Canada licensed services specifically for the cannabis industry.
- Operates as a life sciences and biotechnology company in Canada.
How Does ATTBF Make Money?
- Generates revenue through the development and licensing of natural health products and ingredients.
- Sells its proprietary cannabinoid-enhanced nutraceutical, Comfort.
- Provides specialized, Health Canada licensed services to businesses within the Canadian cannabis industry.
- Aims to monetize intellectual property through licensing agreements across various health and wellness markets.
What Industry Does ATTBF Operate In?
Abattis Bioceuticals Corp. operates within the dynamic Canadian healthcare sector, specifically positioned within the Drug Manufacturers - Specialty & Generic industry. This segment is characterized by innovation in natural health products, nutraceuticals, and the burgeoning cannabis industry. The market for natural health products and nutraceuticals continues to expand, driven by increasing consumer interest in wellness and preventative health, offering a fertile ground for Abattis's development and licensing activities. Concurrently, the regulated cannabis market in Canada presents a unique opportunity for companies providing specialized services and cannabinoid-enhanced products. Abattis's focus on developing and licensing ingredients for biological, nutraceutical, bioceutical, and cosmetic markets, alongside its Health Canada licensed services, places it at the intersection of these growth trends. The competitive landscape includes both established pharmaceutical companies and numerous smaller biotechnology firms, all vying for market share in these specialized niches.
Who Are ATTBF's Key Customers?
- Companies in the biological market seeking specialized ingredients.
- Nutraceutical manufacturers and distributors.
- Bioceutical product developers.
- Cosmetic companies requiring natural extractions and ingredients.
- Consumers seeking cannabinoid-enhanced nutraceuticals for pain and inflammation (via Comfort product).
- Businesses operating within the Canadian cannabis industry requiring licensed services.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Key Financial Metrics
Return on equity for Abattis Bioceuticals Corp. stands at -27.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.8%, showing how much profit it generates from its asset base. A current ratio of 0.73 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Abattis Bioceuticals Corp. operates in the Healthcare sector. It is headquartered in Vancouver, CA. ATTBF has traded publicly since 2014.
Financial Health
Abattis Bioceuticals Corp.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.97 places it in the distress zone, a signal of elevated financial risk.
ATTBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ATTBF Latest News
No recent news available for ATTBF.
ATTBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ATTBF.
Price Targets
Wall Street price target analysis for ATTBF.
ATTBF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ATTBF; grades run from A+ (80-100) to F (below 30).
ATTBF OTC Market Information
Abattis Bioceuticals Corp. trades on the OTC Other tier, which is the lowest of the three primary OTC market tiers (OTCQX, OTCQB, and OTC Pink, which includes OTC Other). Companies on the OTC Other tier are typically those that do not meet the financial or disclosure standards for OTCQX or OTCQB, or that have not provided adequate current information to OTC Markets Group. This tier is often characterized by companies with limited public information, potentially distressed financials, or those in early development stages. Unlike exchanges like NYSE or NASDAQ, which have strict listing requirements for financials, governance, and share price, OTC markets have varying tiers with progressively less stringent rules, with "OTC Other" being the most speculative tier.
- OTC Tier: OTC Other
- **Limited Information Availability**: The "Unknown" disclosure status means critical financial and operational data may not be readily available, hindering informed investment decisions.
- **Extreme Liquidity Risk**: Very low trading volume and wide bid-ask spreads can make it difficult to enter or exit positions without significant price impact.
- **High Volatility**: Shares on the OTC Other tier can experience extreme price fluctuations due to low liquidity and speculative trading.
- **Lack of Regulatory Oversight**: Less stringent reporting requirements compared to major exchanges increase the risk of fraud or misleading information.
- **Market Perception**: Trading on the lowest OTC tier can negatively impact investor confidence and the company's ability to attract institutional investment.
- Verify the company's current financial statements and operational reports directly from the company or reliable third-party sources.
- Research any recent news, press releases, or corporate actions not reflected in public filings.
- Assess the management team's background, experience, and track record beyond what is publicly available.
- Understand the specific regulatory environment for its products and services in Canada.
- Evaluate the competitive landscape and the company's market position within its niche.
- Scrutinize the company's business model for sustainability and revenue generation.
- Investigate any legal or regulatory actions against the company or its management.
- **Incorporation History**: Incorporated in 1997, indicating a long-standing corporate existence.
- **Health Canada Licensing**: Provides Health Canada licensed services, suggesting adherence to specific regulatory standards in the cannabis industry.
- **Defined Product Offerings**: Development and licensing of natural health products and a specific cannabinoid-enhanced nutraceutical ("Comfort") indicate tangible business activities.
- **Identified Headquarters**: Headquartered in Vancouver, Canada, providing a physical base of operations.
Abattis Bioceuticals Corp. Healthcare Stock: Key Questions Answered
What are the key growth opportunities for ATTBF in healthcare?
Abattis Bioceuticals Corp. has several key growth opportunities within the healthcare sector. One significant area is the expansion of its cannabinoid-enhanced nutraceuticals, such as "Comfort," to meet increasing consumer demand for natural solutions to pain and inflammation.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- CEO background and track record are not provided in the source data.
- Specific market sizes and timelines for growth opportunities are estimates based on general industry trends, as not explicitly provided in the source data.
- OTC analysis is based on the provided tier and disclosure status, supplemented by general knowledge of OTC market characteristics.
- The Beta value of -46.51 is exceptionally high and negative, which may indicate data anomaly or extreme inverse correlation; it is reported as provided without further interpretation.